CA2592972A1 - Methods to bypass cd+4 cells in the induction of an immune response - Google Patents
Methods to bypass cd+4 cells in the induction of an immune response Download PDFInfo
- Publication number
- CA2592972A1 CA2592972A1 CA002592972A CA2592972A CA2592972A1 CA 2592972 A1 CA2592972 A1 CA 2592972A1 CA 002592972 A CA002592972 A CA 002592972A CA 2592972 A CA2592972 A CA 2592972A CA 2592972 A1 CA2592972 A1 CA 2592972A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- hla
- immunogen
- antigen
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 151
- 230000028993 immune response Effects 0.000 title claims abstract description 59
- 230000006698 induction Effects 0.000 title description 17
- 230000002163 immunogen Effects 0.000 claims abstract description 145
- 239000000203 mixture Substances 0.000 claims abstract description 81
- 102000036639 antigens Human genes 0.000 claims description 159
- 108091007433 antigens Proteins 0.000 claims description 159
- 239000000427 antigen Substances 0.000 claims description 158
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 144
- 210000004027 cell Anatomy 0.000 claims description 56
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 230000000091 immunopotentiator Effects 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 230000003053 immunization Effects 0.000 claims description 26
- 238000002649 immunization Methods 0.000 claims description 26
- 210000001165 lymph node Anatomy 0.000 claims description 26
- 210000004324 lymphatic system Anatomy 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 230000004913 activation Effects 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 23
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 23
- 241001115402 Ebolavirus Species 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 241000712461 unidentified influenza virus Species 0.000 claims description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 208000031886 HIV Infections Diseases 0.000 claims description 13
- 241000712079 Measles morbillivirus Species 0.000 claims description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 108091054438 MHC class II family Proteins 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 210000002751 lymph Anatomy 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 102000043131 MHC class II family Human genes 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 2
- 230000003278 mimic effect Effects 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 60
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 238000002255 vaccination Methods 0.000 abstract description 10
- 210000000987 immune system Anatomy 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000001900 immune effect Effects 0.000 abstract description 3
- 244000000010 microbial pathogen Species 0.000 abstract description 3
- 230000009447 viral pathogenesis Effects 0.000 abstract description 3
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 95
- 108010058607 HLA-B Antigens Proteins 0.000 description 83
- 102000006390 HLA-B Antigens Human genes 0.000 description 83
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 72
- 241000700721 Hepatitis B virus Species 0.000 description 58
- 241000711549 Hepacivirus C Species 0.000 description 56
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 55
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 53
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 51
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 49
- 108010075704 HLA-A Antigens Proteins 0.000 description 45
- 102000011786 HLA-A Antigens Human genes 0.000 description 45
- 206010022000 influenza Diseases 0.000 description 30
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 24
- 241000701806 Human papillomavirus Species 0.000 description 24
- 241000725643 Respiratory syncytial virus Species 0.000 description 23
- 230000003612 virological effect Effects 0.000 description 23
- 241000700584 Simplexvirus Species 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- 241000701022 Cytomegalovirus Species 0.000 description 17
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 17
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 15
- 208000037797 influenza A Diseases 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 101710122228 Epstein-Barr nuclear antigen 2 Proteins 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 13
- 230000005867 T cell response Effects 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108010039075 HLA-B8 Antigen Proteins 0.000 description 11
- 108010054198 HLA-B*27:05 antigen Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002434 immunopotentiative effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102220378376 HLA-B*2705 Human genes 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 108010033369 HLA-B57 antigen Proteins 0.000 description 7
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102000002689 Toll-like receptor Human genes 0.000 description 7
- 108020000411 Toll-like receptor Proteins 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000001461 cytolytic effect Effects 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 6
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 210000005210 lymphoid organ Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 108010004141 HLA-B35 Antigen Proteins 0.000 description 5
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 108060006580 PRAME Proteins 0.000 description 5
- 102000036673 PRAME Human genes 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 101710122231 Epstein-Barr nuclear antigen 3 Proteins 0.000 description 4
- 241000531123 GB virus C Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 102220391613 HLA-B*2702 Human genes 0.000 description 4
- 108010075326 HLA-B51 Antigen Proteins 0.000 description 4
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 4
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 4
- 108010010995 MART-1 Antigen Proteins 0.000 description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
- 101710122233 Epstein-Barr nuclear antigen 4 Proteins 0.000 description 3
- 101710122229 Epstein-Barr nuclear antigen 6 Proteins 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
- 108010013698 HLA-B17 antigen Proteins 0.000 description 3
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 3
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 3
- 108010037618 HLA-C*08 antigen Proteins 0.000 description 3
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011330 nucleic acid test Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 description 2
- HVUSPTXVKJVJLC-KFFSJVQZSA-N (2s,3s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]am Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C1=CC=C(O)C=C1 HVUSPTXVKJVJLC-KFFSJVQZSA-N 0.000 description 2
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 108010069621 Epstein-Barr virus EBV-associated membrane antigen Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 2
- 108010089211 HLA-A*25 antigen Proteins 0.000 description 2
- 102220372951 HLA-A*3101 Human genes 0.000 description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
- 108010028440 HLA-B*46:01 antigen Proteins 0.000 description 2
- 108010087017 HLA-B14 Antigen Proteins 0.000 description 2
- 108010014398 HLA-B42 antigen Proteins 0.000 description 2
- 108010014597 HLA-B44 Antigen Proteins 0.000 description 2
- 108010057769 HLA-C*03:04 antigen Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 description 2
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108010029973 Lymphocytic choriomeningitis virus glycoprotein peptide Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101800001020 Non-structural protein 4A Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101150037769 TRX2 gene Proteins 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 101710130522 mRNA export factor Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 208000009305 pseudorabies Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229950009795 tucaresol Drugs 0.000 description 2
- VPOQHEDQPXVVEK-PUYUYYSSSA-N (2r)-2-[[(2s,3s)-2-[[(2s)-1-[(2r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-met Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O VPOQHEDQPXVVEK-PUYUYYSSSA-N 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 101150009389 BZLF1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010058155 HA (255-262) Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108010073434 HLA-A*02:09 antigen Proteins 0.000 description 1
- 108010080347 HLA-A*26 antigen Proteins 0.000 description 1
- 108010034115 HLA-A29 antigen Proteins 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 1
- 108010017588 HLA-B*52:01 antigen Proteins 0.000 description 1
- 108010021736 HLA-B15 Antigen Proteins 0.000 description 1
- 108010075646 HLA-B18 Antigen Proteins 0.000 description 1
- 108010083104 HLA-B22 antigen Proteins 0.000 description 1
- 108010070087 HLA-B37 Antigen Proteins 0.000 description 1
- 108010034908 HLA-B52 Antigen Proteins 0.000 description 1
- 108010043021 HLA-B58 Proteins 0.000 description 1
- 108010026301 HLA-C*01:02 antigen Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 101100427508 Human cytomegalovirus (strain AD169) UL39 gene Proteins 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 101710145242 Minor capsid protein P3-RTD Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010036616 P18-I10 peptide Proteins 0.000 description 1
- 101100161152 Pan troglodytes Patr-A gene Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 101150098008 Patr-A gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101150093191 RIR1 gene Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 101800000483 Surface protein gp120 Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 108010051667 glutamyl-glutamyl-asparagyl-leucyl-leucyl-aspartyl-phenylalanyl-valyl-arginyl-phenylalanine Proteins 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 108010003486 leucyl-leucyl-phenylalanyl-glycyl-tyrosyl-prolyl-valyl-tyrosyl-valine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 108010031238 lymphocytic choriomeningitis virus nucleoprotein peptide 118-126 Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical compound [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64082104P | 2004-12-29 | 2004-12-29 | |
| US60/640,821 | 2004-12-29 | ||
| PCT/US2005/047442 WO2006071990A2 (en) | 2004-12-29 | 2005-12-29 | Methods to bypass cd+4 cells in the induction of an immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2592972A1 true CA2592972A1 (en) | 2006-07-06 |
Family
ID=36615526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002592972A Abandoned CA2592972A1 (en) | 2004-12-29 | 2005-12-29 | Methods to bypass cd+4 cells in the induction of an immune response |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8703142B2 (enExample) |
| EP (1) | EP1838342A2 (enExample) |
| JP (1) | JP2008526764A (enExample) |
| AU (1) | AU2005321905A1 (enExample) |
| CA (1) | CA2592972A1 (enExample) |
| IL (1) | IL184276A0 (enExample) |
| MX (1) | MX2007008010A (enExample) |
| SG (1) | SG158155A1 (enExample) |
| WO (1) | WO2006071990A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| CA2612516C (en) | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US7511119B2 (en) | 2005-06-17 | 2009-03-31 | Mannkind Corporation | PRAME peptide analogues |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2657849A1 (en) | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
| EP2129389B1 (en) * | 2007-02-15 | 2014-10-08 | MannKind Corporation | A method for enhancing t cell response |
| EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| JP2010528591A (ja) * | 2007-05-23 | 2010-08-26 | マンカインド コーポレイション | マルチシストロン性ベクター及びそれらの設計方法 |
| EP2167537A2 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Compiled methods for analysing and sorting samples |
| WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| US20110195090A1 (en) * | 2008-10-11 | 2011-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Method of making a vaccine |
| WO2011050344A2 (en) | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| MX360823B (es) | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| JP6484558B2 (ja) | 2012-11-28 | 2019-03-13 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 癌ワクチンの組み合せ物 |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015199617A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | A monoclonal antibody with t-cell receptor-like specificity that targets epstein-barr infected human tumour cells based on their expression of ebna1 |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| CN107921127B (zh) * | 2015-05-22 | 2022-04-08 | 纪念斯隆-凯特琳癌症中心 | 对于prame肽具有特异性的t细胞受体样抗体 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| US12258373B2 (en) | 2018-12-17 | 2025-03-25 | Immudex Aps | Panel comprising Borrelia MHC multimers |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) * | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| IL133912A0 (en) * | 1997-07-10 | 2001-04-30 | Ctl Immunotherapies Corp | A method of inducing ctl response |
| US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| CA2350911A1 (en) * | 1998-11-16 | 2000-05-25 | Board Of Regents, The University Of Texas System | Hiv-specific t-cell induction |
| EP1267618A1 (en) * | 2000-03-28 | 2003-01-02 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
| DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| EP1372736A4 (en) * | 2001-03-07 | 2004-11-17 | Mannkind Corp | PREPARATIONS AGAINST CANCER FORMATION |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| CN1691964A (zh) | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
| ATE546153T1 (de) * | 2003-06-17 | 2012-03-15 | Mannkind Corp | Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen |
| MXPA05013973A (es) * | 2003-06-17 | 2006-03-02 | Mannkind Corp | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| JP2008503494A (ja) * | 2004-06-17 | 2008-02-07 | マンカインド コーポレイション | 診断方法を治療方法と統合することによる免疫療法の効力改善 |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| EP2332971B1 (en) * | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
| AU2005321898B2 (en) * | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| EP2351576A1 (en) * | 2004-12-29 | 2011-08-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| KR101294290B1 (ko) * | 2004-12-29 | 2013-08-07 | 맨카인드 코포레이션 | 예방 또는 치료를 위해 제ｉ류 주조직 적합성복합체〔ｍｈｃ〕-제한 에피토프에 대한 면역 반응을 유발,향상 및 지속하는 방법 |
| KR20080033271A (ko) * | 2005-06-17 | 2008-04-16 | 맨카인드 코포레이션 | 암종을 위한 다가 동반이행 및 증폭형 면역치료제 |
| CA2612516C (en) * | 2005-06-17 | 2015-03-24 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US7511119B2 (en) * | 2005-06-17 | 2009-03-31 | Mannkind Corporation | PRAME peptide analogues |
| US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
-
2005
- 2005-12-29 EP EP05855931A patent/EP1838342A2/en not_active Withdrawn
- 2005-12-29 AU AU2005321905A patent/AU2005321905A1/en not_active Abandoned
- 2005-12-29 MX MX2007008010A patent/MX2007008010A/es not_active Application Discontinuation
- 2005-12-29 WO PCT/US2005/047442 patent/WO2006071990A2/en not_active Ceased
- 2005-12-29 US US11/323,520 patent/US8703142B2/en not_active Expired - Fee Related
- 2005-12-29 SG SG200908487-2A patent/SG158155A1/en unknown
- 2005-12-29 JP JP2007549646A patent/JP2008526764A/ja active Pending
- 2005-12-29 CA CA002592972A patent/CA2592972A1/en not_active Abandoned
-
2007
- 2007-06-28 IL IL184276A patent/IL184276A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005321905A1 (en) | 2006-07-06 |
| JP2008526764A (ja) | 2008-07-24 |
| US20080124352A1 (en) | 2008-05-29 |
| US8703142B2 (en) | 2014-04-22 |
| WO2006071990A9 (en) | 2006-12-07 |
| EP1838342A2 (en) | 2007-10-03 |
| SG158155A1 (en) | 2010-01-29 |
| WO2006071990A2 (en) | 2006-07-06 |
| IL184276A0 (en) | 2007-10-31 |
| MX2007008010A (es) | 2007-09-07 |
| WO2006071990A3 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8703142B2 (en) | Methods to bypass CD4+ cells in the induction of an immune response | |
| ES2358642T3 (es) | Vectores de expresión que codifican epítopos de antígenos y métodos para su diseño. | |
| Eliasson et al. | M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection | |
| Eickhoff et al. | Highly conserved influenza T cell epitopes induce broadly protective immunity | |
| Fuller et al. | Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases | |
| Adar et al. | A universal epitope-based influenza vaccine and its efficacy against H5N1 | |
| EP1787654B1 (en) | Intralymphatic immunization for inducing sustained effector CTL responses | |
| US6977074B2 (en) | Method of inducing a CTL response | |
| Lo et al. | Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies | |
| Raychaudhuri et al. | Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. | |
| Cheong et al. | Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope | |
| Wang et al. | Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice | |
| Voeten et al. | Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8+ cytotoxic T lymphocytes | |
| Rajčáni et al. | Peptide vaccines: new trends for avoiding the autoimmune response | |
| Chiale et al. | Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge | |
| Choi et al. | Enhancement of DNA vaccine-induced immune responses by influenza virus NP gene | |
| Bazhan et al. | A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T-and B-cell epitopes of HIV-1 proteins | |
| Whitton et al. | Principles of cytotoxic T lymphocyte induction and recognition | |
| Edwards et al. | OPEN ACCESS EDITED BY | |
| Amer | Progress in developing hepatitis C virus prophylactic and therapeutic vaccines | |
| Karpenko et al. | CombiHIV vac vaccine which contains polypepitope B-and T-cell immunogens of HIV-1. | |
| Aldovini et al. | New AIDS vaccine candidates: antigen delivery and design | |
| Melief | Synthetic vaccines | |
| Scheel et al. | A novel, disruptive vaccination technology | |
| Franke et al. | Update on Antiviral DNA Vaccine Research (2000–2003) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |